GLP-1 Drugs May Protect Against Cancer, Studies Suggest
New research presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting suggests that GLP-1 receptor agonist drugs — including Ozempic, Wegovy, Mounjaro, and Zepbound — may have significant cancer-protective effects that go beyond their well-known benefits for weight loss and diabetes management. Multiple large-scale observational studies indicate that these medications are associated with reduced cancer risk and slower cancer progression across several tumor types, and researchers are now racing to understand the underlying mechanisms.
Mounting Evidence Across Multiple Cancers
The most prominent study, led by Dr. Mark Orland of the Cleveland Clinic’s Taussig Cancer Institute, tracked medical and prescription records of over 10,000 patients with early-stage cancer and found that GLP-1 use was associated with reduced progression to metastatic disease in six out of seven cancer types studied. Statistically significant reductions were seen in four cancers: non-small cell lung cancer (50% risk reduction), breast cancer (43% risk reduction), colorectal cancer (31% risk reduction), and hepatocellular carcinoma (38% risk reduction), according to findings published in the Journal of Clinical Oncology.
“With 20 million Americans on GLP-1 receptor agonists, these findings are immediately clinically relevant,” Dr. Orland said during an ASCO press briefing, as reported by the Cleveland Clinic Journal of Medicine. “Our study found that use of GLP-1 drugs, compared to DPP-4 inhibitors and other antidiabetic drugs, was associated with a meaningful reduction in cancer progression across four solid tumor types. It provides early evidence that future studies are worth pursuing.”
Breast Cancer Risk Reduction
In a separate landmark study, researchers at Penn Medicine’s Abramson Cancer Center analyzed data from 111,646 women aged 45 to 80 with a BMI of 25 or above. The study, published in JCO Oncology Practice and presented at ASCO, found that women taking GLP-1 medications were approximately 30% less likely to develop breast cancer. The protective effect held even after rigorous statistical matching for age, race, ethnicity, BMI, breast density, and diabetes status.
Dr. Elizabeth McDonald, a professor of radiology at Penn and lead author of the study, noted that the benefits appeared to exceed what could be explained by weight loss alone. “The weight loss alone just didn’t account for the magnitude of the observed effect,” McDonald told NPR. “While our study was observational and does not definitively confirm an association, it does add to the growing body of evidence suggesting that it’s worth investigating these weight-loss drugs as potential cancer prevention tools.”
A Biological Clue: GLP-1 Receptors on Tumors
Further analysis of data from The Cancer Genome Atlas provided a potential biological explanation for the findings. High tumor expression of the GLP-1 receptor independently predicted a 33% lower risk of death across the seven tumor types studied, with the association particularly pronounced in breast cancer, where it correlated with a 45% lower risk of death.
Dr. Kelvin Lee, director of the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, explained to NBC News that “if you target a receptor on the tumor cells, it could interfere with communication and not allow it to be as good at spreading.” He added that the drugs may also interfere with glycolysis, effectively cutting off a tumor’s energy supply.
Beyond Weight Loss: Potential Mechanisms
Researchers are exploring several possible mechanisms behind the apparent cancer-protective effects. GLP-1 drugs are known to reduce chronic inflammation, which creates a tumor-friendly environment. They also improve insulin sensitivity, lowering levels of insulin and IGF-1 that can promote cancer cell growth. Additionally, the drugs may have direct anti-tumor effects by acting on GLP-1 receptors found on tumor cells and modulating immune system activity.
Dr. Marcin Chwistek of Fox Chase Cancer Center, an ASCO expert, emphasized the significance of the findings in comments to the ASCO Post. “GLP-1 RAs have never been just glucose-lowering drugs. Their anti-inflammatory and immune-modulatory properties have long suggested broader effects. What’s new here is the consistency across tumor types, and data this large and this consistent warrant a prospective randomized trial.”
Important Caveats and Next Steps
All studies presented at ASCO 2026 are observational — they show correlation but cannot prove causation. Researchers used sophisticated statistical methods to control for confounding factors, but unmeasured variables such as diet, exercise, and socioeconomic status could still influence results. Randomized controlled trials are needed to establish causality.
Dr. Julie Gralow, chief medical officer of ASCO, told NPR that the data is consistent with what is known about how obesity drives about a dozen cancers and how healthy living is significant in both illness and recovery. “It ties into a body of knowledge about exercise and healthy lifestyles after a cancer diagnosis,” she said.
New trials are already underway. Dr. Coral Omene of Rutgers Cancer Institute, for example, plans to follow 40 breast cancer patients starting tirzepatide, regularly measuring blood samples and tracking changes in cancer markers to understand how the drugs affect immune cells and inflammation.
What This Means for Patients
With approximately 20 million Americans currently taking GLP-1 receptor agonists, the potential public health implications are enormous. If confirmed through randomized clinical trials, these drugs could become a new tool in cancer prevention and treatment, particularly for obesity-related cancers. However, experts emphasize that GLP-1s are not yet ready to be recommended as cancer treatments, and patients should discuss the emerging evidence with their healthcare providers.
For now, the research provides compelling justification for further investigation — and for patients already taking GLP-1s for diabetes or obesity, the possibility of additional cancer-protective benefits offers a promising new dimension to their treatment.